Arizona State Retirement System increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,900 shares of the biopharmaceutical company’s stock after buying an additional 100 shares during the period. Arizona State Retirement System’s holdings in Regeneron Pharmaceuticals were worth $9,283,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the stock. National Pension Service boosted its position in shares of Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after buying an additional 6,481 shares during the period. Grandfield & Dodd LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 17 shares during the period. Highbridge Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $323,000. Princeton Capital Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 157 shares during the period. Finally, CIBC World Markets Inc. boosted its position in shares of Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock valued at $8,442,000 after buying an additional 20,833 shares during the period. Institutional investors own 66.70% of the company’s stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 466.59 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The stock has a market cap of $49.47 billion, a P/E ratio of 46.81 and a beta of 1.66. The company’s 50-day moving average price is $495.54 and its 200-day moving average price is $426.50.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.82 earnings per share. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.84 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://stocknewstimes.com/2017/08/12/arizona-state-retirement-system-buys-100-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html.
Several equities analysts recently commented on the company. Vetr cut Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 target price for the company. in a research report on Monday, May 15th. Robert W. Baird cut Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price for the company. in a research report on Tuesday, August 1st. Zacks Investment Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Credit Suisse Group cut Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 target price for the company. in a research report on Friday, July 14th. Finally, Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average price target of $489.35.
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 9,295 shares of the firm’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $458.14, for a total value of $4,258,411.30. Following the completion of the sale, the chairman now owns 414,156 shares of the company’s stock, valued at $189,741,429.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Robert E. Landry sold 526 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total transaction of $248,371.94. Following the completion of the sale, the senior vice president now directly owns 9,099 shares of the company’s stock, valued at approximately $4,296,456.81. The disclosure for this sale can be found here. In the last three months, insiders sold 56,922 shares of company stock valued at $27,383,105. 10.40% of the stock is owned by insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.